Foundry Partners LLC trimmed its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 8.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 351,533 shares of the medical instruments supplier’s stock after selling 34,312 shares during the quarter. Foundry Partners LLC’s holdings in AngioDynamics were worth $7,642,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Granahan Investment Management Inc. MA boosted its stake in AngioDynamics by 13.3% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 468,099 shares of the medical instruments supplier’s stock worth $10,411,000 after purchasing an additional 54,794 shares during the period. Principal Financial Group Inc. boosted its position in shares of AngioDynamics by 2.7% during the 1st quarter. Principal Financial Group Inc. now owns 298,168 shares of the medical instruments supplier’s stock valued at $5,143,000 after acquiring an additional 7,871 shares during the last quarter. Chicago Equity Partners LLC boosted its position in shares of AngioDynamics by 63.0% during the 2nd quarter. Chicago Equity Partners LLC now owns 66,535 shares of the medical instruments supplier’s stock valued at $1,480,000 after acquiring an additional 25,710 shares during the last quarter. First Trust Advisors LP boosted its position in shares of AngioDynamics by 18.2% during the 2nd quarter. First Trust Advisors LP now owns 41,709 shares of the medical instruments supplier’s stock valued at $928,000 after acquiring an additional 6,414 shares during the last quarter. Finally, Tributary Capital Management LLC bought a new position in shares of AngioDynamics during the 2nd quarter valued at approximately $9,681,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

A number of research analysts have recently commented on ANGO shares. BidaskClub downgraded AngioDynamics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 1st. Canaccord Genuity reiterated a “hold” rating and set a $20.00 target price on shares of AngioDynamics in a research report on Thursday, July 12th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Finally, Raymond James downgraded AngioDynamics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 11th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AngioDynamics currently has an average rating of “Buy” and an average price target of $18.44.

NASDAQ ANGO opened at $20.59 on Friday. The company has a quick ratio of 1.55, a current ratio of 2.64 and a debt-to-equity ratio of 0.16. The company has a market cap of $776.21 million, a PE ratio of 27.16 and a beta of 0.86. AngioDynamics, Inc. has a one year low of $15.16 and a one year high of $24.49.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). The firm had revenue of $85.34 million for the quarter, compared to the consensus estimate of $84.05 million. AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The firm’s revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.13 earnings per share. On average, sell-side analysts expect that AngioDynamics, Inc. will post 0.85 EPS for the current year.

AngioDynamics Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Recommended Story: Do stock splits help investors?

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.